capecitabine
information and resources from the National Cancer Institute
capecitabine
A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. capecitabine
A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand.
Xeloda
Accel. Approv. (clinical benefit subsequently established) Treatment of metastatic breast cancer resistant to both paclitaxel and an anthracycline containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy may be contraindicated, e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents
Roche Apr 30 1998
Xeloda
Initial therapy of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5_FU/LV has not been demonstrated with Xeloda monotherapy.
Roche Apr 30 2001
Xeloda
Treatment in combination with docetaxel of patients with metastatic breast cancer after failure of prior anthracycline containing chemotherapy
Roche Sep 07 2001
|
|
|
|
news articles
Health Canada Approves Xeloda (Capecitabine) for Adjuvant Therapy ... Mar 28, 2006
DG News ...announced today that Health Canada has approved Xeloda (capecitabine), an innovative oral chemotherapy, for the adjuvant treatment of patients with stage III ...
Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum ... Mar 30, 2006
PR Newswire (press release), ...of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the ...
Phase II Trial of Taxotere® and Xeloda® for Metastatic Gastric ... Mar 30, 2006
Cancer Consultants (press release), ...metastatic adenocarcinoma of the stomach or gastroesophageal junction with the chemotherapy drugs Taxotere® (docetaxel) and Xeloda® (capecitabine) reduced or ...
Committee for Medicinal Products for Human Use Post-authorisation ... Mar 24, 2006
PharmaLive.com (press release), Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after ...
Former Texas Gov. Ann Richards has esophagus cancer Mar 9, 2006
Food Consumer, ...for example - compares four regimens containing epirubicin and either cisplatin or oxaliplatin and either continuously infused fluorouracil or capecitabine. ...
Neoadjuvant Docetaxel, Doxorubicin and Capecitabine Used in Women ... Dec 13, 2005
DG News SAN ANTONIO, TX -- December 13, 2005 -- The neoadjuvant combination of docetaxel (T), doxorubicin (A) and capecitabine (X) has demonstrated an encouraging ...
Bortezomib (Velcade) and Capecitabine (Xeloda) in Combination ... Dec 9, 2005
DG News SAN ANTONIO, TX -- December 9, 2005 -- A small phase 1 study has shown that bortezomib (Velcade) used in combination with capecitabine (Xeloda) is safe and well ...
Plenary Session Snapshot Dec 19, 2005
Medscape (subscription) ...the need to identify and test more active chemotherapeutic agents (such as oxaliplatin, a third-generation platinum compound, and capecitabine, an oral ...
WX-UK1 Could Provide Uses Before and During Surgery for Metastatic ... Nov 25, 2005
DG News In their study, Dr. Cohen and colleagues administered WX-UK1 intravenously once weekly in conjunction with capecitabine. Day 1 was ...
Cytokinetics Announces Clinical and Non-Clinical Results for ... Nov 17, 2005
PR Newswire (press release), The two clinical poster presentations highlighted data from two Phase Ib combination trials, one evaluating ispinesib in combination with capecitabine and the ...
(PRN) Cytokinetics Announces Presentation of Ispinesib Data at San ... Dec 8, 2005
Houston Chronicle, ...and breast cancers and three Phase Ib clinical trials designed to evaluate ispinesib in combination with each of docetaxel, carboplatin and capecitabine. ...
(PRN) US Oncology Research Network Presenting Numerous Studies at ... Dec 11, 2005
Houston Chronicle, Results of a Phase II Trial of Combination Therapy with Oral Capecitabine and Weekly Paclitaxel for Metastatic Breast Cancer: Preliminary Results in Taxane Pre ...
Trastuzumab Used as First Line Therapy in Women Whose Cancer Has ... Dec 12, 2005
DG News ...real-life" study. Such agents included paclitaxel and docetaxel, vinorelbine, capecitabine cisplatin and doxorubicin. lead author ...
Xeloda®/Eloxatin®/Avastin® (XeloxA) Highly Active in Newly ... Nov 18, 2005
Cancer Consultants (press release), ...complete and partial remission rate for patients with metastatic colorectal cancer following treatment with treatment with Xeloda (capecitabine) and Eloxatin ...
Molecular Advances Driving New Approaches in Colorectal Cancer ... Nov 18, 2005
DG News Society Institutes of Learning (ONS), Ms. Muehlbauer pointed to the monoclonal antibodies cetuximab and bevacizumab, the oral pro-drug capecitabine, the platin ...
|
|
